Stock Track | TransMedics Group Plummets 24.28% Intraday After Q1 Earnings Severely Miss Estimates, Prompting Analyst Downgrades

Stock Track05-07

TransMedics Group, Inc. (TMDX) experienced a sharp intraday decline of 24.28% on Wednesday, as the medical technology company's stock came under significant selling pressure following the release of disappointing first-quarter financial results.

The plunge was primarily driven by the company's Q1 fiscal year 2026 earnings report, which revealed a severe miss on profitability metrics. TransMedics reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of $0.61 by approximately 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and the company's gross margin narrowed to 58% from 61% a year ago due to higher operating expenses including increased investments in research and development.

The earnings shortfall triggered multiple analyst downgrades and price target reductions throughout the trading session. Firms including Needham, TD Cowen, JP Morgan, Stifel, and Oppenheimer all cut their price targets on the stock, with some also lowering their ratings, reflecting heightened concerns over the company's deteriorating profit margins and earnings trajectory despite reiterated full-year revenue guidance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107651176?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107651176","market":"sg","top_or_hot":-1,"title":"Stock Track | TransMedics Group Plummets 24.28% Intraday After Q1 Earnings Severely Miss Estimates, Prompting Analyst Downgrades","media":"Stock Track","content":"<p>TransMedics Group, Inc. (TMDX) experienced a sharp intraday decline of 24.28% on Wednesday, as the medical technology company's stock came under significant selling pressure following the release of disappointing first-quarter financial results.</p><p>The plunge was primarily driven by the company's Q1 fiscal year 2026 earnings report, which revealed a severe miss on profitability metrics. TransMedics reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of $0.61 by approximately 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and the company's gross margin narrowed to 58% from 61% a year ago due to higher operating expenses including increased investments in research and development.</p><p>The earnings shortfall triggered multiple analyst downgrades and price target reductions throughout the trading session. Firms including Needham, TD Cowen, JP Morgan, Stifel, and Oppenheimer all cut their price targets on the stock, with some also lowering their ratings, reflecting heightened concerns over the company's deteriorating profit margins and earnings trajectory despite reiterated full-year revenue guidance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Group Plummets 24.28% Intraday After Q1 Earnings Severely Miss Estimates, Prompting Analyst Downgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Group Plummets 24.28% Intraday After Q1 Earnings Severely Miss Estimates, Prompting Analyst Downgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 00:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransMedics Group, Inc. (TMDX) experienced a sharp intraday decline of 24.28% on Wednesday, as the medical technology company's stock came under significant selling pressure following the release of disappointing first-quarter financial results.</p><p>The plunge was primarily driven by the company's Q1 fiscal year 2026 earnings report, which revealed a severe miss on profitability metrics. TransMedics reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of $0.61 by approximately 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and the company's gross margin narrowed to 58% from 61% a year ago due to higher operating expenses including increased investments in research and development.</p><p>The earnings shortfall triggered multiple analyst downgrades and price target reductions throughout the trading session. Firms including Needham, TD Cowen, JP Morgan, Stifel, and Oppenheimer all cut their price targets on the stock, with some also lowering their ratings, reflecting heightened concerns over the company's deteriorating profit margins and earnings trajectory despite reiterated full-year revenue guidance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"","article_id":"1107651176","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107651176","pubTimestamp":1778084188,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TransMedics Group, Inc. (TMDX) experienced a sharp intraday decline of 24.28% on Wednesday, as the medical technology company's stock came under significant selling pressure following the release of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"个股追踪|TransMedics Group盘中暴跌24.28%Q1盈利严重不及预期促使分析师下调评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"TransMedics Group, Inc. (TMDX) experienced a sharp intraday decline of 24.28% on Wednesday, as the medical technology company's stock came under significant selling pressure following the release of disappointing first-quarter financial results.The plunge was primarily driven by the company's Q1 fiscal year 2026 earnings report, which revealed a severe miss on profitability metrics. TransMedics reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of $0.61 by approximately 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and the company's gross margin narrowed to 58% from 61% a year ago due to higher operating expenses including increased investments in research and development.The earnings shortfall triggered multiple analyst downgrades and price target reductions throughout the trading session. Firms including Needham, TD Cowen, JP Morgan, Stifel, and Oppenheimer all cut their price targets on the stock, with some also lowering their ratings, reflecting heightened concerns over the company's deteriorating profit margins and earnings trajectory despite reiterated full-year revenue guidance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107651176","isCrawlerRequest":true}